1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
World Acceptance Corporation said President and CEO R. Chad Prashad resigned from his executive and board roles, effective April 10, 2026, to pursue other opportunities. The board appointed former CEO Janet L. Matricciani as interim president and CEO effective April 13, 2026, while it searches for a permanent successor. The leadership change is unplanned and the permanent CEO has not been named.
Prashad resigned as president, CEO and director effective April 10, 2026, to pursue other opportunities
Janet L. Matricciani named interim president and CEO effective April 13, 2026; the board has begun a search for a permanent CEO
Prashad's separation includes $1,260,000 in severance payable over 24 months and accelerated vesting of time-based equity awards
Matricciani's employment agreement provides a $83,333 monthly salary for 12 months and a $350,000 signing bonus
OGE Energy director Luther C. Kissam IV told the company on April 13, 2026 that he will resign from the Board at the annual shareholder meeting on May 14, 2026, citing a new chief executive role at another company. The company says the decision is not due to any disagreement over its operations, policies, or practices, and the board will shrink to eight directors at the meeting.
Director Luther C. Kissam IV will not stand for re-election and resigns effective at the May 14, 2026 Annual Meeting
Reason given: he recently accepted a chief executive officer position at another company, which requires him to leave other boards
Board size reduced from nine to eight directors effective with the Annual Meeting; the rest of the nominee slate is unchanged
Meta said directors Hock E. Tan and Tracey T. Travis notified the company on April 8, 2026 that they will not stand for re-election to the Board at the 2026 Annual Meeting of Shareholders. Both will remain directors until that meeting, so the board has no immediate vacancy.
Notice given on April 8, 2026 by Hock E. Tan and Tracey T. Travis
Neither director will stand for re-election at the 2026 Annual Meeting of Shareholders
Both will continue serving as directors until the Annual Meeting date
Effective April 13, 2026, the board of Illumination Acquisition Corp I appointed John DeMarais as Chief Operating Officer. DeMarais, a director in investment banking at Lucid Capital Markets, has worked on over 20 SPAC transactions, which the filing describes as relevant experience for the role.
Appointment effective April 13, 2026, reported in an 8-K dated April 14, 2026
DeMarais joined Lucid Capital Markets, LLC in April 2025 as a Director in investment banking
Prior roles include Craig-Hallum Capital Group (February 2021 to April 2025) and Ernst & Young (August 2017 to February 2021)
Company will enter a standard form indemnification agreement with DeMarais; no related-party transactions disclosed
Concentra Group Holdings Parent, Inc. said Executive Vice President and Chief Medical Officer Dr. John Anderson will retire effective December 31, 2026. The company has started a formal search for his successor and expects to enter a consulting agreement with him to support the transition. The filing includes no financial results or guidance.
Dr. John Anderson notified the company of his retirement on April 10, 2026, effective December 31, 2026.
The company has initiated a formal search for Anderson's successor.
The company expects to enter a Consulting Agreement with Anderson to support the transition of his responsibilities.
Anderson joined Concentra in 1993 and has served as Chief Medical Officer since 2014.
Hershey said Andrew Archambault, its President, US, will leave the company effective May 1, 2026. The company has begun a search for his replacement, and the filing gives no reason for the departure or any details on a successor.
Andrew Archambault, President, US, will leave the company effective May 1, 2026.
The company has begun a search for his replacement.
The filing does not state a reason for the departure or name an interim successor.
Phibro Animal Health director Joyce J. Lee informed the company on April 13, 2026 that she intends to resign from the Board effective April 15, 2026. The filing states her resignation was not due to any disagreement with the company on its operations, policies or practices.
Joyce J. Lee, a Class II Director, intends to resign effective April 15, 2026
Notice was given to the company on April 13, 2026
Filing states no disagreement with the company on operations, policies or practices
Otter Tail Corporation's board elected Tim Rogelstad as President and Tyler Nelson as Vice President and Chief Financial Officer, both effective April 13, 2026, as part of a long-term succession plan. Former CFO Todd Wahlund became Senior Vice President and President of Otter Tail Power Company, and CEO Charles MacFarlane remains CEO after stepping down as President. The filing discloses no financial results, and the changes are presented as planned succession rather than a response to performance.
Tim Rogelstad, 59, elected President on April 13, 2026; previously President of Otter Tail Power Company since 2014
Tyler Nelson, 46, elected Vice President and CFO on April 13, 2026; previously Vice President of Finance and Treasurer
Todd Wahlund stepped down as CFO and was elected Senior Vice President and President of Otter Tail Power Company
Nelson's base salary is $465,000, with a 50% annual cash incentive target and $250,000 long-term incentive target
Corteva named Luke Kissam, former Albemarle chairman, president and CEO, as CEO of New Corteva, the crop protection company that will separate from its seed business, SpinCo, in the fourth quarter of 2026. Kissam joins the company June 1, 2026, and Chief Executive Chuck Magro will become SpinCo CEO at separation, with new executive teams named for both companies. The filing discloses no financial results; the changes set the leadership structure for the planned separation.
Luke Kissam, 61, joins June 1, 2026 as CEO of the Crop Protection Business Unit and becomes New Corteva CEO at separation.
Kissam's employment agreement sets a $1.2 million annual base salary, a 150% short-term incentive target, and a one-time 2026 equity award with a $3.75 million target grant date value.
Jeff Rudolph is named New Corteva CFO; David Johnson becomes SpinCo CFO; Magro becomes SpinCo CEO.
Robert King, Executive Vice President of Crop Protection, becomes a strategic advisor July 1, 2026, and leaves after 2026 year-end, eligible for a $1 million transition bonus.
Marsh & McLennan said Mark McGivney, its Chief Financial Officer, will also become Executive Vice President and Chief Operating Officer, effective April 15, 2026. He will lead the company's inorganic strategies and support CEO John Doyle, while the Marsh Executive Committee continues to report to Doyle.
Base salary of $1,250,000 effective April 15, 2026
Target annual bonus of $3,450,000 starting with the 2026 performance year, awarded in February 2027
Target long-term incentive award of $6,300,000 starting with the 2027 award, plus a $10 million stock unit grant on May 1, 2026 vesting in three equal annual installments beginning May 15, 2027
Harmony Biosciences said CFO Sandip Kapadia stepped down effective April 14, 2026, to pursue other career opportunities, and named Glenn Reicin as his successor effective the same day. The company also reiterated its 2026 net product revenue guidance of $1.0 to $1.04 billion, so the change does not come with a guidance change.
Sandip Kapadia left the CFO role effective April 14, 2026; his separation agreement provides severance under his existing employment and award agreements, in exchange for a release of claims.
Glenn Reicin, age 61, was appointed CFO effective April 14, 2026; he was CFO at Eccogene from October 2024 to October 2025.
Reicin's employment agreement sets a $500,000 annual base salary, a target bonus of 50% of base salary, and an option award with a $3,000,000 grant date fair value vesting over four years.
Harmony reiterated its 2026 net product revenue guidance of $1.0 to $1.04 billion, primarily from WAKIX sales.
LeMaitre Vascular director Bridget Ross notified the board on April 8, 2026 that she will not stand for re-election at the June 2, 2026 annual meeting, and she will serve until then. The board nominated David B. Roberts for a Class II seat to rebalance board classes; he conditionally resigned his Class I seat, and the board will shrink from eight to seven members. The filing describes these changes as administrative and states no disagreements with the company.
Bridget Ross, Class II director, notified the board on April 8, 2026 of her intent not to stand for re-election
David B. Roberts nominated as Class II director; he notified the board on April 9, 2026 of his conditional resignation as a Class I director
Board size reduced from eight to seven members, effective upon Ross's departure; board to have two Class I, two Class II and three Class III directors
Dow's Board appointed Chief Operating Officer Karen S. Carter as Chief Executive Officer effective July 1, 2026, and added her as a director. Current Chair and CEO Jim Fitterling will become Executive Chair on the same date. Stockholders approved all five agenda items at the April 9, 2026 annual meeting, including an increase in shares available under the 2019 Stock Incentive Plan from 125 million to 185 million.
Karen S. Carter, 55, succeeds Jim Fitterling as CEO effective July 1, 2026; Carter has been COO since December 2024
Fitterling remains an employee and becomes Executive Chair; Richard K. Davis continues as Independent Lead Director
Stockholders approved the Plan amendment with 76% of votes cast in favor; all twelve director nominees were re-elected
Board declared a quarterly dividend of 35 cents per share, payable June 12, 2026 to holders of record on May 29, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.